Two Sigma Investments
SPRY icon

Two Sigma Investments’s ARS Pharmaceuticals SPRY Stock Holding History

Two Sigma Investments’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-72,177
Closed -$725K – 4410
2025
Q3 		$725K Buy
+72,177
New +$1.04M ﹤0.01% 2790
2025
Q2 		– Sell
-10,771
Closed -$135K – 3519
2025
Q1 		$135K Sell
10,771
-87,307
-89% -$1.05M ﹤0.01% 2919
2024
Q4 		$1.03M Sell
98,078
-115,987
-54% -$1.62M ﹤0.01% 2155
2024
Q3 		$3.1M Buy
214,065
+167,141
+356% +$1.99M 0.01% 1370
2024
Q2 		$399K Buy
46,924
+26,507
+130% +$235K ﹤0.01% 2470
2024
Q1 		$209K Sell
20,417
-41,308
-67% -$308K ﹤0.01% 2699
2023
Q4 		$338K Buy
61,725
+8,878
+17% +$38.9K ﹤0.01% 2645
2023
Q3 		$200K Sell
52,847
-538,935
-91% -$3.54M ﹤0.01% 2641
2023
Q2 		$3.96M Buy
591,782
+479,801
+428% +$3.2M 0.01% 1033
2023
Q1 		$729K Buy
111,981
+10,835
+11% +$83.2K ﹤0.01% 2035
2022
Q4 		$863K Sell
101,146
-15,654
-13% -$102K ﹤0.01% 1773
2022
Q3 		$617K Sell
116,800
-76,700
-40% -$378K ﹤0.01% 1680
2022
Q2 		$820K Sell
193,500
-207,676
-52% -$724K ﹤0.01% 1625
2022
Q1 		$1.41M Buy
401,176
+9,492
+2% +$41.3K ﹤0.01% 1518
2021
Q4 		$2.61M Buy
391,684
+241,112
+160% +$1.96M 0.01% 1687
2021
Q3 		$1.5M Buy
+150,572
New +$3.71M ﹤0.01% 2240

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Two Sigma Investments's SPRY Position: Q4 2025 in Review

Two Sigma Investments sold out of ARS Pharmaceuticals (SPRY) in Q4 2025, closing a stake of 72,177 shares — an estimated $725K sold.

Two Sigma Investments first reported a position in SPRY in Q3 2021 and held it in 16 quarters. The position peaked at $3.96M in Q2 2023. 189 funds tracked by Wall St. Rank hold SPRY as of Q4 2025.

  • Two Sigma Investments reported no remaining ARS Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Two Sigma Investments sold 72,177 ARS Pharmaceuticals shares in Q4 2025, an estimated $725K.
  • Two Sigma Investments first reported a position in ARS Pharmaceuticals in Q3 2021 and held it in 16 quarters.
  • Two Sigma Investments's ARS Pharmaceuticals position peaked at $3.96M in Q2 2023.
  • 189 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q4 2025.

Based on Two Sigma Investments's 13F filing for Q4 2025, filed 17 Feb 2026.